• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Igc Pharma Inc (NY: IGC )

    0.3514 -0.0001 (-0.03%)
    Official Closing Price Updated: 8:00 PM EDT, Sep 17, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 106,886
    Open 0.3570
    Bid (Size) 0.3502 (7)
    Ask (Size) 0.3525 (495)
    Prev. Close 0.3515
    Today's Range 0.3421 - 0.3598
    52wk Range 0.2501 - 0.9099
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Advances IGC-AD1 Research to Potentially Deliver ‘Breakthrough Treatment’ in Alzheimer’s Disease
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    Exposures Artificial Intelligence Intellectual Property Product Safety
    IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease
    From IGC Pharma, Inc.
    Via Business Wire

    Performance

    YTD
    +27.32%
    +27.32%
    1 Month
    -17.61%
    -17.61%
    3 Month
    -12.37%
    -12.37%
    6 Month
    -7.09%
    -7.09%
    1 Year
    -15.22%
    -15.22%

    More News

    Read More
    The Analyst Verdict: IGC Pharma In The Eyes Of 4 Experts
    Via Benzinga
    BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Announces Stockholders’ Approval of All Disclosed Proposals at 2024 Annual Meeting
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property Regulatory Compliance
    Exposures Artificial Intelligence Intellectual Property Legal
    IGC Announces Results of its 2024 Annual Stockholders Meeting
    From IGC Pharma, Inc.
    Via Business Wire
    InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Releases Preclinical Research Evaluating New Molecule IGC-1C in Treatment of Alzheimer’s Disease
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    Exposures Artificial Intelligence Intellectual Property
    IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease
    From IGC Pharma, Inc.
    Via Business Wire
    InvestorNewsBreaks – IGC Pharma Inc.’s (NYSE American: IGC) AI-Driven Approach Reveals ‘Promising Opportunity’ for IGC-1A to Be a Potential GLP-1 Agonist
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    Exposures Artificial Intelligence Intellectual Property
    IGC Pharma Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 Agonist
    From IGC Pharma
    Via Business Wire
    IGC Stock Earnings: IGC Pharma Beats EPS, Misses Revenue for Q1 2025
    Via InvestorPlace
    BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Releases Q1 2025 Financial, Operational Results Report
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    Exposures Artificial Intelligence Intellectual Property
    IGC Pharma Revenue Declines 51% YoY Due To Completion Of Its Legacy Project In India, Highlights Important Milestones In Alzheimer's Research
    Via Benzinga
    IGC Pharma Reports First Quarter Fiscal 2025 Results
    From IGC Pharma, Inc.
    Via Business Wire
    InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Receives ‘Buy’ Recommendation in AGP’s Analyst Coverage Research Report
    Via Investor Brand Network
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target
    From IGC Pharma, Inc.
    Via Business Wire
    BioMedNewsBreaks — IGC Pharma Inc.’s (NYSE American: IGC) TGR-63 Demonstrates Blood-Brain Barrier Permeability in Preliminary Findings
    Via Investor Brand Network
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile
    From IGC Pharma, Inc.
    Via Business Wire
    BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Releases Positive Data from TGR-63 Preclinical Studies
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    Exposures Artificial Intelligence Intellectual Property
    InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Releases Financial Report for Fiscal Year
    Via Investor Brand Network
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease
    From IGC Pharma, Inc.
    Via Business Wire
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    Via InvestorPlace
    IGC Stock Earnings: IGC Pharma Meets EPS, Beats Revenue for Q4 2024
    Via InvestorPlace
    IGC Reports Financial Results for Fiscal Year Ended March 31, 2024
    From IGC Pharma, Inc.
    Via Business Wire
    BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Execs Slated to Present at Upcoming Ascendiant Capital Markets Event
    Via Investor Brand Network
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets
    From IGC Pharma, Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.